Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Sector Publishing Intelligence Limited (SPi) has been marketing business and market research reports from selected publishers for over five years. SPi offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, SPi is well positioned to coordinate our customers' orders sourced from over 30 global report publishers. We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document. We look forward to being of service to you. If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf. Phone: +44 (0)1305 753769 or Email: office@sectorpublishing.com 2
Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 Summary Global Markets Direct s, Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016, provides in depth analysis on Human Papillomavirus Protein E7 (E7) targeted pipeline therapeutics. The report provides comprehensive information on the Human Papillomavirus Protein E7 (E7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E7 (E7) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E7 (E7) - The report reviews Human Papillomavirus Protein E7 (E7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Human Papillomavirus Protein E7 (E7) targeted 3
therapeutics and enlists all their major and minor projects - The report assesses Human Papillomavirus Protein E7 (E7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Human Papillomavirus Protein E7 (E7) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E7 (E7) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E7 (E7) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Additional Details Publisher : Global Markets Direct Reference : GMDHC0679TDB Number of Pages : 116 Report Format : PDF Publisher Information : Welcome to Global Markets Direct The home of leading edge research and analysis. The Global Markets Direct brand features thousands of high quality company and market research reports across a broad range of industries. Browse or search our collection of reports today to access the latest in business intelligence from some of the world s leading publishers. 4
Table Of Contents for Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 [Updated: 23-11-2016] Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Human Papillomavirus Protein E7 (E7) Overview 9 Therapeutics Development 10 Human Papillomavirus Protein E7 (E7) - Products under Development by Stage of Development 10 Human Papillomavirus Protein E7 (E7) - Products under Development by Therapy Area 11 Human Papillomavirus Protein E7 (E7) - Products under Development by Indication 12 Human Papillomavirus Protein E7 (E7) - Pipeline Products Glance 13 Late Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Human Papillomavirus Protein E7 (E7) - Products under Development by Companies 16 Human Papillomavirus Protein E7 (E7) - Products under Development by Universities/Institutes 20 Human Papillomavirus Protein E7 (E7) - Therapeutics Assessment 22 Assessment by Monotherapy/Combination Products 22 Assessment by Mechanism of Action 23 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Human Papillomavirus Protein E7 (E7) - Companies Involved in Therapeutics Development 28 Abion Inc 28 Advaxis Inc 29 Bioleaders Corporation 30 BioNTech AG 31 Cancer Research Technology Ltd 32 Etubics Corp 33 Formune SL 34 Genexine Inc 35 Genticel S.A. 36 ibio Inc 37 Immunovaccine Inc 38 Inovio Pharmaceuticals Inc 39 Kite Pharma Inc 40 MedImmune LLC 41 Selecta Biosciences Inc 42 Tomegavax Inc 43 Transgene SA 44 VLPbio 45 Human Papillomavirus Protein E7 (E7) - Drug Profiles 46 ABN-301 - Drug Profile 46 Product Description 46 5
Mechanism Of Action 46 R&D Progress 46 Antibodies to Inhibit E7 for HPV Associated Cancer - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 Aptamer to Target HPV E7 Protein for Cervical Cancer - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 axalimogene filolisbac - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 BLSILSB-710c - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 CerviVax - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 DPXE-7 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 EDA-HPVE7 - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 Enzymes to Inhibit HPV E7 for Human Papillomavirus Related Cervical Cancer - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 ETBX-041 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 GLBL-101c - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 GTL-001 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 6
GTL-002 - Drug Profile 79 Product Description 79 Mechanism Of Action 79 R&D Progress 79 GX-188E - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 human papillomavirus [Serotype 16] vaccine - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 human papillomavirus [serotype 16] vaccine 2 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 human papillomavirus [serotypes 16] vaccine - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 human papillomavirus vaccine - Drug Profile 85 Product Description 85 Mechanism Of Action 85 R&D Progress 85 INO-3106 - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 INO-3112 - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 PVX-01 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 SEL-701 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 TA-CIN - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 TG-4001 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 Vaccine for HPV Associated Cervical Cancer - Drug Profile 95 Product Description 95 Mechanism Of Action 95 7
R&D Progress 95 Vaccine to Target HPV E7 Protein for Cervical Cancer - Drug Profile 96 Product Description 96 Mechanism Of Action 96 R&D Progress 96 Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 97 Product Description 97 Mechanism Of Action 97 R&D Progress 97 VGX-3100 - Drug Profile 98 Product Description 98 Mechanism Of Action 98 R&D Progress 98 Vvax-001 - Drug Profile 101 Product Description 101 Mechanism Of Action 101 R&D Progress 101 Human Papillomavirus Protein E7 (E7) - Dormant Projects 102 Human Papillomavirus Protein E7 (E7) - Discontinued Products 104 Human Papillomavirus Protein E7 (E7) - Featured News & Press Releases 105 Nov 14, 2016: Inovios Cancer Immunotherapy (INO-3112) Generates T Cell Immune Responses in Tumor Tissue and Peripheral Blood in Patients with HPV-Associated Head and Neck Cancer 105 Nov 11, 2016: Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting 106 Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed 107 Oct 24, 2016: Advaxis Announces GOG-0265 12-month Overall Survival Rate of 37.5% in Stage 2 107 Oct 20, 2016: Advaxis Initiates Phase 3 Study of Axalimogene Filolisbac 108 Oct 12, 2016: Inovio Expands Executive Team to Advance its DNA Immunotherapy Product Portfolio 109 Oct 11, 2016: Advaxis Research Reception at SITC 2016 to Review Recent AXAL Highlights and the AXAL-Durvalumab Combination Poster 110 Sep 26, 2016: Advaxis Lm Technology Immunotherapies to be Showcased in Three Poster Presentations at SITC Annual Meeting 110 Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage 110 Jul 26, 2016: Phase 1/2 Combination Trial of AXAL and Durvalumab Completes Second Dose- Escalation Cohort 111 Jul 21, 2016: Advaxis AXAL Receives Fast Track Designation by the FDA as Adjuvant Therapy for High-Risk Locally Advanced Cervical Cancer Patients 111 Jul 18, 2016: European Medicines Agency Committee Classifies Advaxis Axalimogene Filolisbac as an Advanced-Therapy Medicinal Product 112 Jul 06, 2016: FDA Grants Special Protocol Assessment to Advaxis Phase 3 Study of AXAL in Patients with Cervical Cancer 113 Jul 06, 2016: Genticel Appoints Eumedix as Strategic Advisor to Support Company S Access to Innovative Drug Candidates 114 Jun 23, 2016: Genticel Reports 18 Month Interim Analysis of GTL001 Phase 2 Trial in HPV16/18 Infected Women 114 Appendix 115 8
Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116 9
List Of Tables in Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 [Updated: 23-11-2016] List of Tables Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Comparative Analysis by Unknown Stage Development, H2 2016 15 Number of Products under Development by Companies, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Products under Investigation by Universities/Institutes, H2 2016 21 Assessment by Monotherapy/Combination Products, H2 2016 22 Number of Products by Stage and Mechanism of Action, H2 2016 23 Number of Products by Stage and Route of Administration, H2 2016 25 Number of Products by Stage and Molecule Type, H2 2016 27 Pipeline by Abion Inc, H2 2016 28 Pipeline by Advaxis Inc, H2 2016 29 Pipeline by Bioleaders Corporation, H2 2016 30 Pipeline by BioNTech AG, H2 2016 31 Pipeline by Cancer Research Technology Ltd, H2 2016 32 Pipeline by Etubics Corp, H2 2016 33 Pipeline by Formune SL, H2 2016 34 Pipeline by Genexine Inc, H2 2016 35 Pipeline by Genticel S.A., H2 2016 36 Pipeline by ibio Inc, H2 2016 37 Pipeline by Immunovaccine Inc, H2 2016 38 Pipeline by Inovio Pharmaceuticals Inc, H2 2016 39 Pipeline by Kite Pharma Inc, H2 2016 40 Pipeline by MedImmune LLC, H2 2016 41 Pipeline by Selecta Biosciences Inc, H2 2016 42 Pipeline by Tomegavax Inc, H2 2016 43 Pipeline by Transgene SA, H2 2016 44 Pipeline by VLPbio, H2 2016 45 Dormant Projects, H2 2016 102 Dormant Projects (Contd..1), H2 2016 103 Discontinued Products, H2 2016 104 10
List Of Figures, Charts and Diagrams in Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 [Updated: 23-1- -2016] List of Figures Number of Products under Development for, H2 2016 10 Number of Products under Development by Therapy Area, H2 2016 11 Number of Products under Development by Top 10 Indication, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 13 Comparative Analysis by Early Stage Products, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 22 Number of Products by Stage and Mechanism of Actions, H2 2016 23 Number of Products by Routes of Administration, H2 2016 24 Number of Products by Stage and Routes of Administration, H2 2016 24 Number of Products by Molecule Types, H2 2016 26 Number of Products by Stage and Molecule Type, H2 2016 26 11
How to Buy... Human Papillomavirus Protein E7 (E7) - Pipeline Review, H2 2016 [Updated: 23-11-2016] Option 1 - Online Go to our website and pay online with any major debit or credit card: Option 2 - Request a Proforma Invoice Fill in the details below, and either Scan this page and email it to us at office@sectorpublishing.com or Fax it to us at +44 (0)1305 791844.We will send you a Proforma Invoice and deliver your report on settlement. Your Name: Job Title: Your Email: Your Contact Phone: Company Name: Address: Post/Zip Code: Country: P.O. Number: Any Other Instructions: Pricing Options: (please tick one) $3500 Single User Price $7000 Site License Price $10500 Global License Price Payment Options: (please tick one) Online Credit Card (we will email you the invoice with a payment link) Direct Wire Transfer (we will email you the invoice with our bank details) Authorising Signature: Option 3 - Phone Us on +44 (0)1305 753769 We will be delighted to give you our personal attention. 12